IP Library › Granted Patent US 12,577,532
Granted Patent B2
US 12,577,532 · App. 17/613,993 · Granted Mar 17, 2026

Xeno-free and transgene-free reprograming of mesenchymal stem cells toward neural progenitor cells

Inventors: Kiminobu Sugaya (Orlando, FL); Luis Sebastian Alexis Valerio (La Chorrera, PA)
Assignees: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.; INSTITUTE FOR SCIENTIFIC RESEARCH AND TECHNOLOGY SERVICES (INDICASAT)
C12N5/0623A61K35/30C12N2500/38C12N2500/40C12N2501/06C12N2501/11C12N2501/113C12N2501/91C12N2502/088C12N2506/1346
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,577,532
App. No.
17/613,993
Granted
Mar 17, 2026
Kind
B2
Abstract

Disclosed herein are methods and materials for transdifferentiating mesenchymal stem cells into neural progenitor cells.

Claims (6)

1 . A method of reprogramming mesenchymal stem cells as neural progenitor cells, the method comprising (a) modifying epigenetic status of mesenchymal stem cells by (i) subjecting the mesenchymal stem cells to a first media comprising 5-aza-2′-deoxycytidine; (ii) removing the first media from the mesenchymal stem cells, and (iii) subjecting the mesenchymal stem cells from step (ii) to a second media comprising SB431542; and (b) contacting the mesenchymal stem cells of step (a) with extracellular vesicles obtained from neural stem cells under conditions to allow the mesenchymal stem cells to convert into neural progenitor cells.

2 . The method of claim 1 , wherein contacting step (b) comprises (iv) culturing the mesenchymal stem cells in media with neural stem cell (NSC) exosomes for 1-5 days; after step (iv), (v) refreshing the media and NSC exosomes and culturing the cells for 5-15 days; and after step (v), (vi) providing fresh media lacking NSC exosomes and culturing the cells for at least 5-7 days, wherein the cells of step (vi) form spheres.

3 . The method of claim 2 , further comprising isolating spheres from step (vi).

4 . The method of claim 2 , wherein step (v) starts at day 4, 5, or 6 from the start of step (iv); and step (vi) starts at day 14, 15, or 16 from the start of step (a).

5 . The method of claim 1 , wherein contacting step (b) results in formation of spheres, and the method further comprises (c) isolating the spheres.

6 . The method of claim 1 , wherein the extracellular vesicles comprise exosomes.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2022
From: SUGAYA, KIMINOBU
To: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
Reel/Frame 059486/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2022
From: VALERIO, LUIS SEBASTIAN ALEXIS
To: INSTITUTE FOR SCIENTIFIC RESEARCH AND TECHNOLOGY SERVICES (INDICASAT)
Reel/Frame 059486/0898 →
Continuity (2)
Provisional Application 62852388 · May 24, 2019
Related Publication 20220348867A1 · Nov 3, 2022
References Cited (15)
US 20090304647A1 · Qu · 2009 [cited by examiner]
US 20160130554A1 · Almeida-Porada et al. · 2016 [cited by applicant]
US 20170267971A1 · Han · 2017 [cited by examiner]
US 20190119666A1 · Kim · 2019 [cited by applicant]
WO 2017155166A1 · 2017 [cited by applicant]
WO WO2017155166 · 2017 [cited by examiner]
WO 2020243091A1 · 2020 [cited by applicant]
Takeda et al., Neuronal Differentiation of Human Mesenchymal Stem Cells Using Exosomes Derived from Differentiating Neuronal Cells, PLoS ONE, 10(8), (2015), pp. 1-15. [cited by examiner]
Diomede et al., 5-Aza Exposure Improves Reprogramming Process Through Embryoid Body Formation in Human Gingival Stem Cells, Frontiers in Genetics, vol. 9, Article 419, (2018), pp. 1-11. [cited by examiner]
Christman, 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy, Oncogene, vol. 21, (2002), pp. 5483-5495. [cited by examiner]
PCT/US2020/034553, PCT Search Report & Written Opinion, mailed Oct. 15, 2020, 12 pages. [cited by applicant]
Kassis, I. et al., “Isolation of mesenchymal stem cells from G-CSF-mobilized human peripheral blood using fibrin microbeads”. [cited by applicant]
Kern, Susanne et al., “Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Umbilical Cord Blood, or Adipose Tissue”, Stem Cells, 2006, vol. 24, pp. 1294-1301. [cited by applicant]
Valerio, Luis Sebastian Alexis et al., “Xeno- and transgene-free reprogramming of mesenchymal stem cells toward the cells expressing neural markers using exosome treatments”, Plos One, Oct. 13, 2020, 14 pages. [cited by applicant]
Zhang, Yi et al., “Comparison of mesenchymal stem cells from human placenta and bone marrow”, Chinese Medical Journal, 2004, vol. 117, issue 6, pp. 882-887. [cited by applicant]